Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ShangPharma (SHP) IPO prices tonight (Mon) for trading Oct 19

|Includes: APRI, BASI, CBTEQ, CLDA, CRL, CVD, ICLR, LLY, PPDI, SHA, ShangPharma Corporation (SHP), SRLS, WX

ShangPharma (NYSE:SHP), $90mm IPO with a market cap of $289mm
At the IPO price range mid-point of $15.5
Scheduled for Tuesday Oct 19, 2010

SHP  valuation metrics:  compare with WX

Biopharma outsourcing in China
. On a P/E baisis is priced on par with the larger one-on-one competitor WuXi Pharma (NYSE:WX)
. On price-to-book value SHP is priced at a 25%+ discount to WX
. SHA may be able to grow at a faster rate from a smaller basis than WX.
Each ADS represents 18 ordinary shares

. A leading China-based pharmaceutical and biotechnology research and development, or R&D, outsourcing company.
. Provides a broad range of high-quality, integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies. Our services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services.

. Provides services to over 100 customers, including all of the top ten pharmaceutical and biotechnology companies in the world in terms of 2009 revenues ranked by Frost & Sullivan and a number of fast-growing biotechnology and specialty pharmaceutical companies, as well as renowned academic and research institutions in the U.S. and China.
. Most customers return for additional and often larger projects, and all of the top ten customers in each of 2008 and 2009 remain our customers in 2010.

. Competes with WuXi PharmaTech across the breadth of the service offerings.
. Also competes with industry participants in certain service areas, for example with Albany Molecular Research, Inc. in discovery chemistry and pharmaceutical development, and Cerep S.A. and Covance Inc. in discovery biology and preclinical development.

$43mm from sale of 3.2mm ADSs.  Shareholders intend to sell 2.6mm ADSs
• $15.0 million for the construction of a manufacturing facility and laboratory services building in Fengxian, Shanghai;
• $15.0 million for the purchase of equipment;
• $5.0 million for the expansion of service offerings;
• $5.0 million for working capital needs;
• balance for other general corporate purposes

SHP  valuation metrics: compare with WX

Disclosure: none